Discovering New Precision Medicines
Building on an exceptional track record of innovation, this team brings a wealth of cross-functional expertise to successful rational drug design. We focus on pioneering best-in-class therapeutics to improve upon existing drugs with clear liabilities, as well as to create new breakthroughs for diseases where others have been unable to find solutions.
Established and emerging science will guide our plans, with an emphasis on rare disease patient populations with well-characterized biology, allowing us to move rapidly and create meaningful impact for patients.
Inhibition Ligand Independent Signaling in FGFR 2/3 Altered Tumors is a Clinically Proven Approach